H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Research

• Publication date

  2017-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-16-2925PMID 27872088
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling.

  2015cited by this paper
• Rare codons capacitate Kras-driven de novo tumorigenesis.

  2015cited by this paper
• Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

  2015influential reference
• Recent advances in RASopathies

  2015cited by this paper
• K-RasV14I recapitulates Noonan syndrome in mice

  2014cited by this paper
• Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ *

  2014cited by this paper
• Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway

  2014cited by this paper
• Rare codons regulate KRas oncogenesis.

  2013influential reference
• Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma

  2013cited by this paper
• Trametinib: First Global Approval

  2013cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012cited by this paper
• Ras trafficking, localization and compartmentalized signalling.

  2012cited by this paper
• c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

  2011cited by this paper
• Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations

  2011cited by this paper
• Echocardiography in Mice.

  2011cited by this paper
• Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation.

  2010cited by this paper
• Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene

  2009cited by this paper
• The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

  2009cited by this paper
• K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

  2008cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• Kras regulatory elements and exon 4A determine mutation specificity in lung cancer

  2008cited by this paper
• A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition.

  2008cited by this paper
• Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.

  2007cited by this paper
• Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.

  2007cited by this paper
• Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay.

  2007cited by this paper
• Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders

  2006cited by this paper
• In-gel digestion for mass spectrometric characterization of proteins and proteomes

  2006cited by this paper
• Germline mutations in HRAS proto-oncogene cause Costello syndrome

  2005cited by this paper
• Replacement of K‐Ras with H‐Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice

  2005cited by this paper
• Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

  2004cited by this paper
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

  2004cited by this paper
• Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

  2004cited by this paper
• Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

  2003cited by this paper
• RAS oncogenes: the first 30 years

  2003cited by this paper
• Adenovirus-5 E1A: paradox and paradigm

  2002cited by this paper
• Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

  2001cited by this paper
• Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development

  2001cited by this paper
• Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

  1997cited by this paper
• K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

  1997influential reference
• K-Ras is essential for the development of the mouse embryo

  1997cited by this paper
• Efficient in vivo manipulation of mouse genomic sequences at the zygote stage.

  1996cited by this paper

• Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review

  2025cites this paper
• The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations

  2025cites this paper
• Inflammation and aging: signaling pathways and intervention therapies

  2023cites this paper
• Papillomas of Costello syndrome are not associated with human papillomavirus (HPV) infection in a small case series.

  2023cites this paper
• Navigating the ERK1/2 MAPK Cascade

  2023cites this paper
• RAS oncogene signal strength regulates matrisomal gene expression and tumorigenicity of mouse keratinocytes.

  2022cites this paper
• 40 Years of RAS—A Historic Overview

  2021cites this paper
• KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

  2021cites this paper
• Targeting KRAS mutant lung cancer: light at the end of the tunnel

  2021cites this paper
• RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions.

  2021cites this paper
• Mutation bias within oncogene families is related to proliferation-specific codon usage

  2020cites this paper
• Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

  2020cites this paper
• Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck

  2020cites this paper
• Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.

  2020cites this paper
• The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease

  2020cites this paper
• The Frequency of Ras Mutations in Cancer

  2020cites this paper
• The Frequency of Ras Mutations in Cancer A C

  2020cites this paper
• Proliferation specific codon usage facilitates oncogene translation

  2019cites this paper
• Unravelling lung cancer heterogeneity and associated therapeutic responses using in vivo and ex vivo model systems

  2018cites this paper
• A model for RAS mutation patterns in cancers: finding the sweet spot

  2018cites this paper
• ERF deletion rescues RAS deficiency in mouse embryonic stem cells

  2018cites this paper
• The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer

  2018cites this paper
• Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

  2017cites this paper
• Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma

  2017influential citation